Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
Kayoko MorioJun WatanabeYasushi TsujimotoPublished in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2020)